Myfortic in pediatric transplantation

Pediatric Transplantation

Volumn 12, Issue 6, 2008, Pages 614-616

  Zimmerhackl, Lothar Bernd ^a   Jungraithmayr, Therese ^a   Wiesmayr, Silke ^a,c   Filler, Guido ^b  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b Department of Pediatrics ^*  (Canada)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN A; METHYLPREDNISOLONE; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER;

ACUTE GRAFT REJECTION; AREA UNDER THE CURVE; BLOOD TOXICITY; CHRONIC GRAFT REJECTION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EDITORIAL; GASTROINTESTINAL SYMPTOM; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; INFECTION; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; NEOPLASM; NEUTROPENIA;

AREA UNDER CURVE; CHILD; GASTROINTESTINAL DISEASES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; IMP DEHYDROGENASE; LYMPHOCYTES; MODELS, BIOLOGICAL; MYCOPHENOLIC ACID; ORGAN TRANSPLANTATION; PEDIATRICS; TABLETS, ENTERIC-COATED;

EID: 49349097185     PISSN: 13973142     EISSN: 13993046     Source Type: Journal    
DOI: 10.1111/j.1399-3046.2008.00979.x     Document Type: Editorial

References (25)

1. Zimmerhackl LB, Wiesmayr S, Kirste G, Jungraithmayr T. Mycophenolate mofetil (Cellcept) in pediatric renal transplantation. Transplant Proc 2006: 38: 2038 2040.
2. Jungraithmayr TC, Wiesmayr S, Staskewitz A, et al. Five-year outcome in pediatric patients with mycophenolate mofetil-based renal transplantation. Transplantation 2007: 83: 900 905.
3. Millan O, Oppenheimer F, Brunet M, et al. Assessment of mycophenolic acid-induced immunosuppression: A new approach. Clin Chem 2000: 46: 1376.
4. Langman LJ, LeGatt DF, Halloran PF, Yatscoff RW. Pharmacodynamic assessment of mycophenolic acid-induced immunosuppression in renal transplant recipients. Transplantation 1996: 62: 666 672.
5. Weber LT, Shipkova M, Armstrong VW, et al. The pharmacokinetic- pharmacodynamic relationship for total and free mycophenolic acid in pediatric renal transplant recipients: A report of the german study group on mycophenolate mofetil therapy. J Am Soc Nephrol 2002: 13: 759 768.
6. Behrend M. Adverse gastrointestinal effects of mycophenolate mofetil: Etiology, incidence and management. Drug Saf 2001: 24: 645 663.
7. Mele TS, Halloran PF. The use of mycophenolate mofetil in transplant recipients. Immunopharmacology 2000: 47: 215 245.
8. Arns W, Gies M, Choi L, et al. Absorption characteristics of EC-MPS - an enteric-coated formulation of mycophenolic sodium. Int J Clin Pharmacol Ther 2006: 44: 375 385.
9. Salvadori M, Holzer H, de Mattos A, et al. Enteric-coated mycophenolate sodium is therapeutically equivalent to mycophenolate mofetil in de novo renal transplant patients. Am J Transplant 2004: 4: 231.
10. Salvadori M, Holzer H, Civati G, et al. Long-term administration of enteric-coated mycophenolate sodium (EC-MPS, Myfortic) is safe in kidney transplant patients. Clin Nephrol 2006: 66: 112.
11. Budde K, Curtis J, Knoll G, et al. Enteric-coated mycophenolate sodium can be safety administered in maintenance renal transplant patients: Results of a 1-year study. Am J Transplant 2004: 4: 237.
12. Budde K, Knoll G, Curtis J, et al. Long-term safety and efficacy after conversion of maintenance renal transplant recipients from mycophenolate mofetil (MMF) to enteric-coated mycophenolate sodium (EC-MPS, myfortic). Clin Nephrol 2006: 66: 102.
13. Kobashigawa JA, Renlund DG, Gerosa G, et al. Similar efficacy and safety of enteric-coated mycophenolate sodium (EC-MPS, myfortic) compared with mycophenolate mofetil (MMF) in de novo heart transplant patients: Results of a 12-month, single-blind, randomized, parallel group, multicenter study. J Heart Lung Transplant 2006: 25: 935.
14. Johnston A, He X, Holt DW. Bioequivalence of enteric-coated mycophenolate sodium and mycophenolate mofetil: A meta-analysis of three studies in stable renal transplant recipients. Transplantation 2006: 15: 82.
15. Cattaneo D, Cortinovis M, Baldelli S, et al. Pharmacokinetics of mycophenolate sodium and comparison with the mofetil formulation in stable kidney transplant recipients. Clin J Am Soc Nephrol 2007: 2: 1147 1155 (epub 2007 Oct 10).
16. Budde K, Bauer S, Hambach P, et al. Pharmacokinetic and pharmacodynamic comparison of enteric-coated mycophenolate sodium and mycophenolate mofetil in maintenance renal transplant patients. Am J Transplant 2007: 00: 888 898.
17. Budde K, Glander P, Kramer BK, et al. Conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in maintenance renal transplant recipients receiving tacrolimus: Clinical, pharmacokinetic, and pharmacodynamic outcomes. Transplantation 2007: 83: 417 424.
18. Kaplan B, Meier-Kriesche H-U, Minnick P, et al. Randomized calcineurin inhibitor cross over study to measure the pharmacokinetics of co-administered enteric-coated mycophenolate sodium. Clin Transplant 2005: 19: 551.
19. Hesselink DA, van Hest RM, Mathot RA, et al. Cyclosporine interacts with mycophenolic acid by inhibiting the multidrug resistance-associated protein 2. Am J Transplant 2005: 5: 987.
20. Shipkova M, Armstrong VW, Kuypers D, et al. Effect of cyclosporine withdrawal on mycophenolic acid pharmacokinetics in kidney transplant recipients with deteriorating renal function: Preliminary report. Ther Drug Monit 2001: 23: 717.
21. Zucker K, Rosen A, Tsaroucha A, et al. Unexpected augmentation of mycophenolic acid pharmacokinetics in renal transplant patients receiving tacrolimus and mycophenolate mofetil in combination therapy, and analogous in vitro findings. Transpl Immunol 1997: 5: 225.
22. Miras M, Carballo F, Egea J, et al. Clinical evolution in the first 3 months of patients after liver transplantation in maintenance phase converted from mycophenolate mofetil to mycophenolate sodium due to gastrointestinal complications. Transplant Proc 2007: 39: 2314 2317.
23. Pelletier RP, Soule J, Henry ML, Rajab A, Ferguson RM. Clinical outcomes of renal transplant recipients treated with enteric-coated mycophenolic acid vs. mycophenolate mofetil as a switch agent using a primary steroid-free rapamune and microemulsion cyclosporine protocol. Clin Transplant 2007: 21: 532 535.
24. Bolin P, Tanriover B, Zibari GB, et al. Improvement in 3-month patient-reported gastrointestinal symptoms after conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in renal transplant patients. Transplantation 2007: 84: 1443 1451.
25. Pape L, Ahlenstiel T, Kreuzer M, Ehrich J. Improved gastrointestinal symptom burden after conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in kidney transplanted children. Pediatr Transplant 2008: 12: 640 642.